Takeda Announces Termination Of License Agreement For Tavocept(TM) In Japan

Main Category: Pharma Industry / Biotech Industry
Also Included In: Lymphology/Lymphedema
Article Date: 17 Nov 2006 - 0:00 PDT

Current ratings for:
'Takeda Announces Termination Of License Agreement For Tavocept(TM) In Japan'

Patient / Public:1 star

1 (1 votes)

Healthcare Prof:not yet rated


ASKA Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Company Limited announced the termination of the License Agreement of March 15, 2006 that had previously been entered into by Takeda, ASKA, KI Pharmaceuticals, Inc.(*) and BioNumerik Pharmaceuticals, Inc. with respect to the investigational new drug known as Tavocept(TM) for the territory of Japan. Tavocept(TM) (generic name: dimesna) is an investigational new drug with potential for oncology and non-oncology indications that was originated and developed by BioNumerik.

Takeda decided to terminate this License Agreement in view of its global product strategy and in connection with the termination of a separate agreement on Tavocept(TM) between Takeda and BioNumerik for the U.S. and Canada territories, which was announced on October 24, 2006.

KI Pharma and ASKA will continue to be involved with Tavocept(TM) development in the territory of Japan, which now is in the phase 3 stage.

KI Pharma is a joint venture formed by ASKA and BioNumerik.

About Tavocept(TM)

Tavocept(TM) is an investigational new drug with potential for oncology and non-oncology indications that was originated and developed by BioNumerik. Tavocept has potential applicability in multiple therapeutic areas including chemotherapy induced neuropathy, diabetic neuropathy, protection against toxicity from radiation therapy, lymphedema and other potential medical indications.

About ASKA

ASKA, located in Tokyo, Japan, is a research and development (R&D) oriented company, which contributes to the society by developing and providing innovative pharmaceutical products with concentrating its management resources to the specific therapeutic areas. Additional information about ASKA, is available through its corporate website, http://www.aska-pharma.co.jp/english/index.html.

About KI Pharma

KI Pharma, located in Tokyo, Japan, is a joint venture formed by ASKA and BioNumerik that is aimed at developing a broad portfolio of new compounds to distribute and market in Japan.

About Takeda Pharmaceutical

Takeda Pharmaceutical, located in Osaka, Japan, is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate website, http://www.takeda.com/index-e.html.

Takeda Pharmaceutical
http://www.takeda.com/index-e.html

Article adapted by Medical News Today from original press release.
Visit our pharma industry / biotech industry section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Christopher Backing. "Takeda Announces Termination Of License Agreement For Tavocept(TM) In Japan." Medical News Today. MediLexicon, Intl., 17 Nov. 2006. Web.
26 May. 2012. <http://www.medicalnewstoday.com/releases/56915.php>

APA
Christopher Backing. (2006, November 17). "Takeda Announces Termination Of License Agreement For Tavocept(TM) In Japan." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/56915.php.

Please note: If no author information is provided, the source is cited instead.



Add Your Opinion On This Article

'Takeda Announces Termination Of License Agreement For Tavocept(TM) In Japan'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Your Name:*
E-mail Address:*
Your Opinion Title:*
Opinion:*
This is to help prevent SPAM submissions. Please enter the words exactly as they appear, including capital letters and punctuation.*

* Fields marked with a * need to be filled in before you hit the submit button.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.


Pharma Industry / Biotech Industry

Most Popular Articles



Follow Our Pharma Industry News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Pharma Industry / Biotech Industry Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »